Eagle Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>EP</div>
EGRX -- USA Stock  

USD 39.35  0.45  1.16%

It appears Eagle Pharmaceuticals may not have a good chance to recover from the current slide as its shares fell again. This firm's current daily volatility is 2.54 percent, with a beta of -0.03 and an alpha of -0.17 over DOW. While many traders are getting carried away by overanalyzing market volatility, it is reasonable to break down Eagle Pharmaceuticals based on how it reacts to the current economic swings. We will cover the possibilities of making Eagle Pharmaceuticals into a steady grower in September.
Published over a month ago
View all stories for Eagle Pharmaceuticals | View All Stories
Should we continue shadow Eagle Pharmaceuticals (NASDAQ:EGRX) executives?
Eagle Pharmaceuticals currently holds roughly 202.02 M in cash with 32.96 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.76. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Eagle Pharmaceuticals has an asset utilization ratio of 130.95 percent. This suggests that the company is making $1.31 for each dollar of assets. An increasing asset utilization means that Eagle Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
Investing in Eagle Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Eagle Pharmaceuticals along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.

How important is Eagle Pharmaceuticals's Liquidity

Eagle Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Eagle Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Eagle Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Eagle Pharmaceuticals's total debt and its cash.

How Eagle utilizes its cash?

To perform a cash flow analysis of Eagle Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Eagle Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Eagle Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Eagle Pharmaceuticals Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Eagle Pharmaceuticals reported Net Cash Flow from Operations of 55.99 Million in 2019

Eagle Pharmaceuticals Correlation with Peers

Investors in Eagle can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Eagle Pharmaceuticals. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Eagle Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Eagle is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Eagle for more details

Acquisition by Robert Glenning of 10000 shares of Eagle Pharmaceuticals subject to Rule 16b-3

Legal trades by Eagle Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Eagle insider trading alert for grant of stock option (right to buy) by Robert Glenning, the corporate stakeholder, on 28th of August 2020. This event was filed by Eagle Pharmaceuticals Inc with SEC on 2018-01-09. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Eagle Pharmaceuticals Investor Appetite?

Eagle Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0794, which denotes the company had -0.0794% of return per unit of risk over the last month. Macroaxis standpoint towards predicting the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Eagle Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Eagle Pharmaceuticals coefficient of variation of (1,546), and Mean Deviation of 1.98 to check the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Will Eagle price slide impact its balance sheet?

Market risk adjusted performance is down to 6.49. It may suggest a possible volatility slide. Eagle Pharmaceuticals exhibits very low volatility with skewness of 0.13 and kurtosis of -0.11. However, we advise investors to further study Eagle Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

Our Final Perspective on Eagle Pharmaceuticals

While many other companies in the drug manufacturers?specialty & generic industry are either recovering or due for a correction, Eagle Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 10th of August 2020, we believe that at this point, Eagle Pharmaceuticals is very steady with low probability of financial unrest within the next 2 years. From a slightly different point of view, the entity appears to be fairly valued. Our present 30 days recommendation on the company is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Eagle Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com